Vivo aims to aid US/Chinese cross-border pacts with $375M fund
This article was originally published in Scrip
Executive Summary
With the closing of a new $375 million fund, Vivo Ventures is not only eyeing to invest in clinical and commercial stage drug and device makers in the US and China, it also is aiming to facilitate cross-border partnerships between companies in those countries, said managing partner Dr Albert Cha.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.